Two major drug companies are the latest to join TrumpRx

Amgen and GSK will be added to TrumpRx.gov, bringing the tally to 54 prescription drugs from six companies under Most-Favored-Nation pricing; Amgen will list Amjevita at $299 (about an 80% reduction from $1,484.18) and plans to list Aimovig and Repatha at ~62% discounts. GSK will list Incruse at $159.20 (55% of retail) and says it will offer Annuity, Relenza and Anoro at discounts ranging roughly 10%–51%. The White House frames this as part of a broader drug-affordability push while PhRMA warns MFN policies could siphon billions from U.S. R&D, creating upside for price-sensitive patients but added policy and margin risk for drugmakers.

Analysis

The announced public-pricing push will compress the list-to-net spread ecosystem-wide and shift bargaining power toward payors and purchasers. Expect realized prices for concentrated, single-product franchises to fall faster than headline list prices as manufacturers choose volume or access over legal fights; that reweights value away from single-molecule names toward diversified platforms and payor-owned channels.

A less-obvious consequence is accelerated vertical repositioning: PBMs and insurers gain leverage to push for formulary steering and broader rebate pass-through, while contract manufacturers and generics stand to pick up incremental volume. Over 6–24 months this can raise utilization of lower-cost alternatives and compress growth multiples on specialty developers whose launches depended on sustained US premium pricing.

Policy durability is the key hinge. In the near term (days–weeks) headline additions create trading volatility; in the medium term (quarters) management guidance and MLR/EBITDA impacts surface; in the long run (years) R&D allocation and pipeline prioritization shift — expect companies to favor programs with shorter time-to-market and clearer global pricing parity. Litigation, legislative pushback, or a change in executive strategy could reverse effects quickly, so monitor legal filings and congressional calendars.

Contrarian read: the market may be overstating permanent cash-flow loss for big diversified pharmas while understating their ability to offset margin pressure with portfolio mix, supply-chain cost saves, and buybacks. Tactical dislocations will exist—especially among mid/small-cap specialists—but large-cap integrated names are more likely to reallocate capital than to suffer terminal declines in valuation.

Key Decisions for Investors

• Pair trade (3–12 months): Long UnitedHealth (UNH) / Short IBB (equal dollars). Rationale: insurers capture a disproportionate share of near-term savings and multiple expansion if medical cost trends ease; target 8–15% relative outperformance. Risk: rapid policy reversal or utilization shock; hedge with 3–6 month UNH puts if announcement cadence accelerates.
• Hedge trade (1–6 months): Buy a 3–6 month AMGN put spread (near-ATM protection financed by selling a further OTM put). Rationale: expresses downside from margin hits to high-volume biologics while capping premium paid. Reward: asymmetric downside protection if guidance is cut; cost = limited premium. Risk: volatility crush if market discounts the policy impact quickly.
• Long generics/volume beneficiaries (6–18 months): Buy TEVA or Viatris (VTRS). Rationale: lower-priced branded access funnels incremental volume to generics/authorized generics and CMOs; upside 15–30% if share gains materialize. Risk: aggressive price competition and regulatory risks; size position accordingly.
• Event hedge (30–120 days): Buy puts on a concentrated mid-cap biotech ETF (e.g., XBI options) or construct a short basket of single-product specialty names trading >3x revenue multiple. Rationale: rapid re-pricing of high-priced launches is the most immediate catalyst. Risk: broad market rally or policy rollback that spares launch economics.